Literature DB >> 11119018

Lipid peroxidation and antioxidant enzyme levels in type 2 diabetics with microvascular complications.

M M Kesavulu1, R Giri, B Kameswara Rao, C Apparao.   

Abstract

Serum levels of total cholesterol, triglycerides, lipoproteins, lipid peroxides (TBARS) and erythrocyte antioxidant enzyme activities were measured in 105 non insulin dependent diabetic patients, among whom 38 had microvascular complications (MVC) of diabetes. All the diabetic patients had higher concentrations of glycated hemoglobin (HbA1) compared to controls (10.51 +/- 2.42% vs 6.31 +/- 0.85% P <0.001). Significant increase of serum triglycerides (TG), total cholesterol (TC), low density lipoprotein cholesterol (LDL-C) and very low density lipoprotein cholesterol (VLDL-C) and a significant decrease of high density lipoprotein cholesterol (HDL-C) were observed in the diabetic patients compared to controls (TG: 2.31 +/- 0.9 mmol/l vs 1.53 +/- 0.48 mmol/l P <0. 001; TC: 5.94 +/- 1.4 mmol/l vs 4.3 +/- 0.85 mmol/l P <0.001; LDL-C: 3.96 +/- 1.33 mmol/l vs 2.39 +/- 0.8 mmol/l P <0.001; VLDL-C: 0.46 +/- 0.2 mmol/l vs 0.3 +/- 0.09 mmol/l P <0.001; HDL-C: 0.81 +/- 0.24 mmol/l vs 1.04 +/- 0.18 mmol/l P <0.001). Significantly increased levels of serum TBARS were observed in diabetic patients compared to those in controls (TBARS: 6.7 +/- 1.5 mmol/l vs 5.14 +/- 0.61 mmol/l P <0.001). Erythrocyte catalase (CAT) activity was increased and Glutathione peroxidase (GPx) activity was decreased in diabetic patients compared to controls, but no significant change in Superoxide dismutase (SOD) activity was observed in diabetic patients (CAT: 104.94 +/- 37.1 KU/g Hb vs 85.8 +/- 23.6 KU/g Hb, P <0.01; GPx: 30 +/- 9.7 U/g Hb/min vs 40.84 +/- 12.3 U/g Hb/min, P <0. 001; SOD: 2.4 +/- 1.2 U/mg Hb/min vs 2.55 +/- 0.84 U/mg Hb/min, P=NS). In comparison with the diabetic group without MVC, the diabetic group with MVC had decreased GPx and SOD activities, while no difference was observed between these two groups regarding CAT activity (GPx: 25.32 +/- 8.4 U/g Hb/min vs 34.5 +/- 8.8 U/g Hb/min, P <0.001; SOD: 1.83 +/- 0.53 U/mg Hb/min vs 2.84 +/- 1.4 U/mg Hb/min, P<0.001; CAT: 106.3 +/- 39.9 KU/g Hb vs 103 +/- 34.9 KU/g Hb, P =NS). TBARS concentrations were significantly increased in the group with MVC compared to the group without these complications, indicating a positive relationship between TBARS and MVC of diabetes (7.05 +/- 1.23 mmol/l vs 6.3 +/- 1.02 mmol/l, P <0.001). Serum triglycerides, LDL and VLDL cholesterol concentration were significantly higher in diabetics with MVC than in diabetics without the complications (TG: 2.7 +/- 0.98 mmol/l vs 2.13 +/- 0.82 mmol/l, P<0.01; LDL - C: 4.45 +/- 1.3 mmol/l vs 3.67 +/- 1.3 mmol/l, P <0. 02; VLDL-C: 0.53 +/- 0.19 mmol/l vs 0.43 +/- 0.16 mmol/l, P <0.01), and the serum levels of TC in the group with MVC showed a positive correlation with their lipid peroxide levels (r =0.368, P <0.001). The increase in TBARS and the decreased GPx and SOD activities in diabetics with MVC in this study indicate that these factors may contribute to the occurrence of micro vascular complications in NIDDM patients.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11119018

Source DB:  PubMed          Journal:  Diabetes Metab        ISSN: 1262-3636            Impact factor:   6.041


  42 in total

Review 1.  Lipid metabolites in the pathogenesis and treatment of neovascular eye disease.

Authors:  Andreas Stahl; Tim U Krohne; Przemyslaw Sapieha; Jing Chen; Ann Hellstrom; Emily Chew; Frank G Holz; Lois E H Smith
Journal:  Br J Ophthalmol       Date:  2011-03-18       Impact factor: 4.638

2.  Neurochemical correlates of alloxan diabetes: glucose and related brain metabolism in the rat.

Authors:  Nayeemunnisa Ahmed; Noor Zahra
Journal:  Neurochem Res       Date:  2010-12-29       Impact factor: 3.996

3.  SR-135, a peroxynitrite decomposing catalyst, enhances β-cell function and survival in B6D2F1 mice fed a high fat diet.

Authors:  Michael Johns; Robert Fyalka; Jennifer A Shea; William L Neumann; Smita Rausaria; Eliwaza Naomi Msengi; Maryam Imani-Nejad; Harry Zollars; Timothy McPherson; Joseph Schober; Joshua Wooten; Guim Kwon
Journal:  Arch Biochem Biophys       Date:  2015-04-29       Impact factor: 4.013

4.  Influence of glutathione S-transferase polymorphisms (GSTT1, GSTM1, GSTP1) on type-2 diabetes mellitus (T2D) risk in an endogamous population from north India.

Authors:  Sarabjit S Mastana; Antarpreet Kaur; Rachel Hale; Martin R Lindley
Journal:  Mol Biol Rep       Date:  2013-11-08       Impact factor: 2.316

5.  The effect of Gongronema latifolium extracts on serum lipid profile and oxidative stress in hepatocytes of diabetic rats.

Authors:  N H Ugochukwu; N E Babady; M Cobourne; S R Gasset
Journal:  J Biosci       Date:  2003-02       Impact factor: 1.826

Review 6.  Justification for antioxidant preconditioning (or how to protect insulin-mediated actions under oxidative stress).

Authors:  A Orzechowski
Journal:  J Biosci       Date:  2003-02       Impact factor: 1.826

Review 7.  Oxidative stress and diabetes: what can we learn about insulin resistance from antioxidant mutant mouse models?

Authors:  Jennalynn Styskal; Holly Van Remmen; Arlan Richardson; Adam B Salmon
Journal:  Free Radic Biol Med       Date:  2011-10-20       Impact factor: 7.376

8.  Erythrocyte caspase-3 and antioxidant defense is activated in red blood cells and plasma of type 2 diabetes patients at first clinical onset.

Authors:  Octavian Savu; Ovidiu Marius Bradescu; Cristian Serafinceanu; Liviu Iosif; Constantin Ionescu Tirgoviste; Irina Stoian
Journal:  Redox Rep       Date:  2013-03-06       Impact factor: 4.412

9.  Morin attenuates hepatic insulin resistance in high-fat-diet-induced obese mice.

Authors:  Jarinyaporn Naowaboot; Supaporn Wannasiri; Patchareewan Pannangpetch
Journal:  J Physiol Biochem       Date:  2016-03-14       Impact factor: 4.158

10.  Plasma coenzyme Q10 levels in type 2 diabetic patients with retinopathy.

Authors:  Orhan Ates; Habip Bilen; Sadullah Keles; H Hakan Alp; Mevlüt Sait Keleş; Kenan Yıldırım; Osman Ondaş; L Can Pınar; Mustafa Civelekler; Orhan Baykal
Journal:  Int J Ophthalmol       Date:  2013-10-18       Impact factor: 1.779

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.